海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《麗珠醫藥集團股份有 限公司關於回購公司股份的進展公告》，僅供參閱。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-046 丽珠医药集团股份有限公司关于回购公司股份的进展公告 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* 公司秘書 劉寧 中國，珠海 二零二五年六月三日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本 公司的非執行董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 、林楠棋先生及邱慶豐先 生 ; 而本公司的獨立非執行董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗 婕女士 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 2024年度股东大会、2025年第一次A股类别股东会及2025年第一次H股类别股东会没有出现否决议案的 情形，未涉及变更以往股东大会已通过的决议。 一、会议的召集、召开和出席情况 1、股东大会届次：丽珠医药集团股份有限公司（以下简称"公司"）2024年度股东大会、2025年第一次 A股类别股东会及2025年第一次H股类别股东会。 2、股东大会的召集人：公司董事会。公司已于2025年4月23日召开了第十一届董事会第二十四次会议， 审议通过了《关于召开公司2024年度股东大会、2025年第一次A股类别股东会及2025年第一次H股类别 股东会的议案》。 3、股东大会的主持人：副董事长陶德胜先生。 ③2025年第一次H股类别股东会召开日期、时间：2025年5月29日（星期四）下午3:30（或紧随公司2025 年第一次A股类别股东会结束后）。 （2）网络投票时间： ①通过互联网投票系统进行网络投票的起止日期和时间：2025年5月29日上午9:15至2025年5月 ...

海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《廣東德賽律師事務所 關於麗珠醫藥集團股份有限公司關於召開 2024 年度股東大會、2025 年第一次 A 股類別 股東會及 2025 年第一次 H 股類別股東會的法律意見書》，僅供參閱。 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. * 公司秘書 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 劉寧 中國，珠海 二零二五年五月二十九日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本 公司的非執行董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 、林楠棋先生及邱慶豐先 生 ; 而本公司的獨立非執行董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗 婕女士。 * 僅供識別 第 ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | | | --- | --- | --- | --- | | 股票發行人現金股息公告 | | | | | 麗珠醫藥集團股份有限公司 | 發行人名稱 | | | | 01513 | 股份代號 | | | | 多櫃檯股份代號及貨幣 | 不適用 | | | | 相關股份代號及名稱 | 不適用 | | | | 2024年12月31日止年度末期股息（更新） | 公告標題 | | | | 2025年5月29日 | 公告日期 | | | | 更新公告 | 公告狀態 | | | | 更新匯率及其他信息 | 更新/撤回理由 | | | | | 股息信息 | | | | 末期 | 股息類型 | | | | 普通股息 | 股息性質 | | | | 2024年12月31日 | 財政年末 | | | | 宣派股息的報告期末 | 2024年12月31日 | | | | 每 10 股 11 RMB | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 於二零二五年五月二十九日舉行之 二零二四年度股東大會、 二零二五年第一次 A 股類別股東會及 二零二五年第一次 H 股類別股東會 投票表決結果 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」）董事會（「董事會」）茲 宣佈，本公司已於二零二五年五月二十九日在中國廣東省珠海市金灣區創業北路38號總部大樓六樓會 議室舉行二零二四年度股東大會（「年度股東大會」）、二零二五年第一次A股類別股東會（「A股類 別股東會」）及二零二五年第一次H股類別股東會（「H股類別股東會」）（統稱「大會」），所有列 載於召開大會的通知內擬提呈會上之決議案已獲本公司股東以投票方式表決通過。 關於在大會上審議的議案詳細內容，已載於本公司日期為二零二五年四月二十四日的通函（「通 函」）。除另有界定者外，本公告所用詞彙與通函所界定者具有相同涵義。 於大會記錄日期當日，本公司已發行股份總 ...

Core Viewpoint - The acquisition of 64.81% stake in Imexpharm Corporation (IMP) by Lijuz Group for 1.587 billion yuan has sparked market discussions primarily due to its high valuation [1]. Group 1: Acquisition Details - The transaction price corresponds to a price-to-earnings (P/E) ratio of 27.6 times IMP's projected net profit for 2024, significantly higher than Lijuz Group's own P/E ratio of 15 times [4]. - If calculated based on the annualized net profit for the first quarter of 2025, the dynamic P/E ratio rises to 29.7 times [4]. - The acquisition price represents a premium of 293.79% over IMP's net assets at the end of 2024, indicating a control premium and a bet on the potential of the Vietnamese pharmaceutical market [4]. Group 2: Company Background and Market Position - IMP, established in 1977, is a leading pharmaceutical company in Vietnam, with core products including antibiotics (first in market share) and cardiovascular drugs (fifth in market share), covering over 80% of medical institutions in Vietnam [4]. - In 2024, IMP reported revenue of 696 million yuan and a net profit of 88.83 million yuan; for the first quarter of 2025, revenue was 186 million yuan with a net profit of 20.61 million yuan [4]. Group 3: Strategic Rationale - The acquisition aims to complement Lijuz Group's existing product lines in antibiotics and cardiovascular drugs, allowing both companies to share research and development resources as well as sales channels [4]. - The Vietnamese pharmaceutical market is growing at an annual rate exceeding 10%, and IMP holds EU GMP certification, which could provide Lijuz Group with a gateway to Southeast Asian and European markets [4]. - Lijuz Group's revenue in 2024 decreased by 4.97% year-on-year, primarily due to price reductions from centralized procurement and a decline in demand for antiviral drugs, necessitating the search for new growth opportunities [4].

R&D Strategy and Product Pipeline - The company has initiated a comprehensive review of its R&D strategy starting in 2024, focusing on clear and defined strategic lines around disease areas and technology platforms [2][3]. - In the gastrointestinal field, the company is expanding its product lineup with P-CAB tablets and injectables, with P-CAB tablets currently in Phase III clinical trials [3]. - The reproductive health sector has a complete product cycle from ovulation induction to luteal support, with a key product, recombinant human follicle-stimulating hormone injection, reported in January 2023 and expected to enhance the product pipeline [3]. - In the field of mental health, the company is advancing its pipeline with innovative products like NS-041 tablets, which have completed Phase I trials and are moving into Phase II [4]. Key Product Developments - NS-041 tablets are positioned as a best-in-class product for epilepsy, showing superior selectivity and efficacy compared to similar products in development, with a patent protection until 2042 [4]. - The small nucleic acid project LZHN2408 has completed IND filing and targets gout with high patient demand, expected to receive clinical approval soon [5]. - The IL-17A/F monoclonal antibody for psoriasis has completed Phase III clinical enrollment and is expected to launch in 2025, with promising clinical data showing a 60% complete skin clearance rate at 12 weeks [6][7]. Business Development and Market Strategy - The company employs a dual strategy of self-research and business development (BD) to enhance its pipeline, focusing on projects that align with its core areas and technology platforms [9]. - The acquisition of Vietnam's IMP company aims to strengthen innovation and global market presence, leveraging IMP's established marketing network and production capabilities [12]. - The company anticipates steady growth in its traditional Chinese medicine sector, driven by products like the ginseng and astragalus injection, benefiting from policy changes [10][11]. Organizational Changes and Efficiency - The company has enhanced its operational efficiency through systematic improvements in R&D project management, optimizing processes and resource allocation [13]. - Structural adjustments have been made to ensure a stable workforce while optimizing roles, particularly in sales, to support product launches and market penetration [13].

Core Viewpoint - Lijun Group is accelerating its overseas market expansion through the acquisition of a majority stake in Imexpharm Corporation (IMP) in Vietnam for approximately 1.587 billion RMB, which is expected to enhance its international presence and product synergy [1][2][3] Group 1: Acquisition Details - Lijun Group's wholly-owned subsidiary, LIAN SGP, plans to acquire 64.81% of IMP for about 57.3 trillion VND, equivalent to approximately 1.587 billion RMB, representing 11.45% of the company's latest audited net assets [2] - The acquisition does not constitute a related party transaction or a major asset restructuring, and upon completion, IMP will be included in Lijun Group's consolidated financial statements [2] - IMP, established in 1977, is a leading pharmaceutical company in Vietnam, focusing on the research, production, and sales of pharmaceuticals, including antibiotics and cardiovascular drugs [2] Group 2: Financial Performance - Lijun Group has shown consistent growth in overseas revenue, with figures of 1.565 billion RMB, 1.571 billion RMB, and 1.724 billion RMB from 2022 to 2024, reflecting year-on-year growth rates of 1.72%, 0.4%, and 9.69% respectively [3] - The overseas gross profit margin reached 48.9% in 2024, marking a ten-year high [3] - The company's net profit has been on a positive growth trajectory since 2019, with a net profit of 637 million RMB in Q1 2025, representing a year-on-year increase of 4.75% [1][5] Group 3: Research and Development - Lijun Group has invested over 1 billion RMB annually in R&D since 2021, with total R&D expenditures amounting to 4.941 billion RMB from 2021 to 2024 [5] - As of the 2024 annual report, the company has 45 projects under development, including 23 innovative drugs and high-barrier complex formulations, with 7 projects in the review stage for market approval [5] Group 4: Shareholder Returns - Lijun Group has a strong track record of returning value to shareholders, having distributed cash dividends 25 times, totaling 10.54 billion RMB, with a dividend payout ratio of 47.75% [5]

Group 1 - Health元 announced that its subsidiary, Lijuz Group, plans to acquire 64.81% of Imexpharm Corporation for approximately 5.73 trillion VND (about 1.587 billion RMB), which represents 11.45% of Lijuz Group's latest audited net assets [1] - Imexpharm Corporation is a Vietnamese pharmaceutical company engaged in the research, production, and sales of drugs, including antibiotics and cardiovascular medications [1] - After the acquisition, Imexpharm will become a subsidiary of Lijuz Group, aiding in the expansion of the group's overseas market [1] Group 2 - Lijuz Group's revenue has been under pressure, with a reported revenue of 11.812 billion RMB in 2024, a decrease of 4.97% year-on-year, while net profit increased by 5.50% to 2.061 billion RMB [2] - The decline in revenue is attributed to price reductions from national medical insurance negotiations affecting key products, as well as decreased sales in antiviral products following reduced demand due to COVID-19 and flu [2] - Health元 also reported a revenue of 15.619 billion RMB in 2024, down 6.17% year-on-year, with a net profit of 1.387 billion RMB, a decrease of 3.90% [2] Group 3 - Lijuz Group is accelerating its international expansion to enhance its risk resilience, with products already covering Southeast Asia, South America, the Middle East, and Africa [3] - The company has initiated the construction of an active pharmaceutical ingredient factory in Indonesia to support local and international production, aiming to reduce costs and improve market responsiveness [3] - In 2024, Lijuz Group achieved overseas revenue of 1.724 billion RMB, a year-on-year increase of 9.69%, accounting for 14.59% of total revenue, which is a 2 percentage point increase from 2023 [3]

Core Viewpoint - Lijuz Group plans to acquire a 64.81% stake in Imexpharm Corporation from SK Investment Vina III Pte.Ltd., Sunrise Kim Investment Joint Stock Company, and KBA Investment Joint Stock Company for approximately 15.87 billion RMB [1] Group 1 - The acquisition price is set at 57,308.15 billion Vietnamese Dong, which is equivalent to about 15.87 billion RMB based on the exchange rate on the date of the agreement [1] - The transaction will not be classified as a related party transaction and does not constitute a major asset restructuring as defined by the regulations [1] - Following the completion of the transaction, Imexpharm Corporation will become a subsidiary included in Lijuz Group's consolidated financial statements [1]